Rocket Lab
RKLB
$63.91
-8.69%
Rocket Lab is a vertically integrated space company that designs and manufactures launch vehicles (Electron and Neutron) and satellite platforms (Photon), providing end-to-end mission services for civil, defense, and commercial markets. As a leading pure-play space stock, it distinguishes itself through frequent and reliable small-to-medium launch capabilities and a growing satellite systems business, positioning itself as a key competitor to SpaceX in the new space economy. The current investor narrative centers on the transformative $8 billion acquisition of Iridium Communications, which promises to dramatically expand Rocket Lab's satellite constellation and recurring revenue base, while the company continues to post record revenue growth and expanding gross margins. However, the stock's recent 37% monthly decline reflects market concerns over integration risks, high valuation, and the path to profitability, creating a sharp debate between bulls betting on a vertically integrated space giant and bears focused on near-term financial losses.…
RKLB
Rocket Lab
$63.91
Related headlines
RKLB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rocket Lab's 12-month outlook, with a consensus price target around $114.33 and implied upside of +78.9% versus the current price.
Average Target
$114.33
0 analysts
Implied Upside
+78.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$77 - $150
Analyst target range
Rocket Lab is covered by 14 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.56 (where 1 is Strong Buy and 5 is Sell). The distribution shows 10 Buy/Overweight ratings, 1 Hold, and 0 Sell, indicating strong bullish sentiment. The average price target is $116.57, implying a massive 72.4% upside from the current price of $67.62. This wide gap between the current price and the average target suggests that analysts believe the recent selloff is overdone and that the fundamental story remains intact. The target range spans from a low of $77.00 to a high of $150.00. The high target of $150.00 assumes successful integration of Iridium, continued revenue acceleration, and eventual profitability, potentially justifying a higher multiple. The low target of $77.00 still implies 13.9% upside, suggesting that even the most bearish analyst sees value at current levels. Recent ratings actions show no downgrades; instead, Keybanc upgraded from Sector Weight to Overweight on June 15, 2026, and all other firms maintained their Buy/Overweight ratings in June. This consistency in bullish sentiment, despite the stock's 37% monthly decline, signals that analysts view the pullback as a buying opportunity rather than a fundamental deterioration. The tight spread between the low and high targets (a range of $73) relative to the average indicates moderate conviction, but the unanimous bullish tilt is notable.
Drowning in data?
Find the real signal!
Bulls vs Bears: RKLB Investment Factors
Rocket Lab presents a high-conviction bull case built on accelerating revenue growth (63.5% YoY), a transformative Iridium acquisition, and strong analyst support with 72% upside to the average target. However, the bear case is equally compelling, centered on extreme valuation (61.5x sales), negative free cash flow (-$316M TTM), and significant integration risks. The single most important tension is whether the Iridium acquisition will successfully transition Rocket Lab to a profitable, recurring-revenue business model, justifying its premium multiple, or whether integration challenges and continued cash burn will lead to multiple compression and further downside. Currently, the evidence slightly favors the bull case given the revenue trajectory and analyst consensus, but the risk/reward is highly asymmetric and demands close monitoring of integration milestones.
Bullish
- Record Revenue Growth Accelerating: Q1 2026 revenue of $200.3 million grew 63.5% year-over-year, up from $122.6 million in Q1 2025, demonstrating accelerating demand for launch and space systems. This growth rate outpaces most aerospace peers and supports the thesis of scaling toward profitability.
- Iridium Acquisition Transforms Business Model: The $8 billion acquisition of Iridium Communications adds a large satellite constellation and recurring revenue base, potentially shifting Rocket Lab from project-based launch revenue to more predictable subscription-like income. This could dramatically improve cash flow visibility and margins over time.
- Strong Analyst Conviction with 72% Upside: The average analyst price target of $116.57 implies 72.4% upside from the current $67.62, with 10 of 14 analysts rating it Buy/Overweight and no Sell ratings. Recent upgrades (e.g., Keybanc to Overweight on June 15) indicate analysts view the pullback as a buying opportunity.
- Expanding Gross Margins Show Operating Leverage: Gross margin improved to 38.2% in Q1 2026 from 28.8% a year earlier, reflecting better product mix and scale benefits. This trend suggests the company is gaining pricing power and cost efficiencies as revenue grows.
Bearish
- Extreme Valuation at 61.5x Sales: The price-to-sales ratio of 61.5x is astronomically high compared to the Aerospace & Defense industry average of 2-5x, implying the market is pricing in years of hyper-growth. Even for high-growth space stocks, this multiple leaves no room for error.
- Negative Free Cash Flow Burns Cash: Trailing twelve-month free cash flow is -$316.3 million, and the price-to-FCF ratio of -223.7x indicates the company relies on external financing. Despite $1.2B cash, the burn rate could require further equity dilution, pressuring the stock.
- Iridium Integration Risks and Dilution: The $8 billion Iridium acquisition introduces significant integration risk, including potential cost overruns, culture clashes, and execution delays. Additionally, the $503 million equity issuance in Q1 2026 dilutes existing shareholders, and further raises may be needed.
- Deeply Unprofitable with Negative Margins: Operating margin of -27.9% and net margin of -22.5% in Q1 2026 show the company is still heavily investing in R&D ($80.5 million) and sales infrastructure. The path to profitability is uncertain, and any slowdown in growth could expose the lack of earnings.
RKLB Technical Analysis
Rocket Lab's 1-year price change of +31.7% masks a dramatic reversal from its 52-week high of $151.00, with the current price of $67.62 sitting at just 27% of the 52-week range (from $37.57 low). This positioning near the lower end of the range suggests the stock is deeply oversold after a sharp correction, potentially offering a value entry if the fundamental thesis holds, but also signaling that momentum has decisively turned negative. The stock's beta of 2.553 indicates it is more than 2.5 times as volatile as the S&P 500, amplifying both upside and downside moves. Over the past three months, RKLB has declined 20.3%, while the S&P 500 gained 4.7%, resulting in a relative strength of -24.9% — a clear sign of severe underperformance. The 1-month price change of -37.4% versus the S&P's +0.3% highlights an accelerating selloff, diverging sharply from the longer-term uptrend and suggesting panic selling or a potential capitulation bottom. This short-term crash contrasts with the 1-year gain, indicating that the stock is in a corrective phase within a longer-term bullish structure, but the velocity of the decline warrants caution. The 52-week low of $37.57 provides a critical support level, while the high of $151.00 represents formidable resistance. A breakdown below $37.57 would signal a complete reversal of the long-term uptrend and likely trigger further selling, while a recovery above $100 would indicate that the correction is over. With a beta of 2.553, RKLB is highly sensitive to market moves, and its current volatility — as seen in the 55.2% maximum drawdown — demands strict risk management for position sizing.
Beta
2.55
2.55x market volatility
Max Drawdown
-57.5%
Largest decline past year
52-Week Range
$38-$151
Price range past year
Annual Return
+32.8%
Cumulative gain past year
| Period | RKLB Return | S&P 500 |
|---|---|---|
| 1m | -25.2% | +0.8% |
| 3m | -19.8% | +3.5% |
| 6m | -28.1% | +7.2% |
| 1y | +32.8% | +16.5% |
| ytd | -15.9% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RKLB Fundamental Analysis
Rocket Lab's revenue trajectory is accelerating sharply, with Q1 2026 revenue of $200.3 million representing 63.5% year-over-year growth, up from $144.5 million in Q2 2025 and $122.6 million in Q1 2025. The sequential growth from Q4 2025's $179.7 million shows continued momentum, driven by both Launch Services and Space Systems segments — the latter benefiting from the Iridium acquisition. Product revenue of $127.5 million and service revenue of $72.9 million in Q1 2026 indicate a balanced mix, though the acquisition will tilt toward services. This growth trajectory supports the bull case that Rocket Lab is scaling rapidly toward profitability, but the deceleration from the 63.5% YoY rate will be key to monitor. Despite strong revenue growth, Rocket Lab remains unprofitable, reporting a net loss of $45.0 million in Q1 2026, though this loss narrowed from $60.6 million in Q1 2025 and $66.4 million in Q2 2025. Gross margin improved to 38.2% in Q1 2026 from 28.8% a year earlier, reflecting better operating leverage and product mix. However, operating margin remains deeply negative at -27.9%, and net margin is -22.5%, indicating that the company is still investing heavily in R&D ($80.5 million in Q1 2026) and sales infrastructure. The trajectory toward profitability is positive but gradual, and the Iridium acquisition may temporarily pressure margins as integration costs ramp up. Rocket Lab's balance sheet is solid with $1.21 billion in cash at the end of Q1 2026, bolstered by $503 million in common stock issuance during the quarter. The debt-to-equity ratio is a low 0.15, and the current ratio of 4.08 indicates ample liquidity. However, free cash flow remains negative at -$77.4 million in Q1 2026 and -$316.3 million on a trailing twelve-month basis, meaning the company is still burning cash to fund growth. The negative FCF yield (price-to-FCF ratio of -223.7) underscores that the company relies on external financing — primarily equity raises — to sustain operations, which dilutes shareholders. The ROE of -11.5% reflects the lack of profitability, but the strong cash position provides a runway for several years.
Quarterly Revenue
$200348000.0B
2026-03
Revenue YoY Growth
+63.5%
YoY Comparison
Gross Margin
38.2%
Latest Quarter
Free Cash Flow
$-316301000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RKLB Overvalued?
Since Rocket Lab has negative net income (EPS of -$0.07 in Q1 2026), the trailing P/E ratio of -188.5 is meaningless, so we lead with the price-to-sales (P/S) ratio. The current P/S ratio of 61.5x is extremely high, reflecting the market's willingness to pay a premium for future growth. The forward P/E of 2,254x, based on estimated EPS of $0.92, implies that analysts expect a dramatic earnings turnaround, but the multiple remains astronomical. Compared to the Aerospace & Defense industry average P/S (not provided, but typically in the 2-5x range for mature firms), Rocket Lab's 61.5x represents a massive premium, justified only by its hyper-growth trajectory and the potential of the Iridium acquisition to create a recurring revenue powerhouse. However, even for high-growth space stocks, this multiple is stretched — for context, SpaceX private valuations have historically traded at 20-30x sales. Rocket Lab's own historical P/S ratio has ranged from 21x in mid-2024 to over 194x in Q1 2026, and the current 61.5x sits near the middle of that range. This suggests that while the stock is not at its most expensive historical level, it is still priced for perfection. The PEG ratio of 71.6x, based on estimated EPS growth, indicates that the market is pricing in years of above-average growth, leaving little room for error. If growth disappoints or the Iridium integration falters, the multiple could contract sharply.
PE
-188.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-234.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Rocket Lab's primary financial risk is its negative free cash flow of -$316.3 million on a trailing twelve-month basis, which, despite $1.21 billion in cash, implies a cash runway of roughly 3-4 years at the current burn rate. The company's net loss of $45.0 million in Q1 2026, though narrowing, means profitability is not imminent, and the operating margin of -27.9% indicates heavy ongoing investment. The $503 million equity issuance in Q1 2026 dilutes shareholders, and if the Iridium acquisition requires additional capital, further dilution could pressure the stock. Revenue concentration is also a risk, as the Space Systems segment (boosted by Iridium) may become overly dominant, exposing the company to project delays or contract cancellations.
Market & Competitive Risks: The stock's valuation of 61.5x sales is a major risk, as any growth deceleration could trigger severe multiple compression. With a beta of 2.553, RKLB is highly sensitive to macro shocks, and the recent 37% monthly decline versus the S&P's flat performance shows it is already under severe selling pressure. Competitive threats from SpaceX (dominant in launch) and AST SpaceMobile (satellite-to-phone) could erode Rocket Lab's market share, especially if Neutron launch delays persist. Regulatory risks include export controls and FCC spectrum allocation, which could impact the Iridium constellation's value. Recent news highlights that AST SpaceMobile's stock surged 31% on Iridium deal validation, indicating that competitors may also benefit from the same tailwinds.
Worst-Case Scenario: In a worst-case scenario, the Iridium integration encounters major cost overruns or technical failures, causing revenue growth to decelerate below 20% and margins to deteriorate. Analysts would downgrade en masse, and the stock could fall to the 52-week low of $37.57, representing a 44.4% decline from the current $67.62. If the company needs to raise equity at depressed prices, dilution could push the stock even lower. The historical max drawdown of -55.2% suggests a realistic downside to around $30, implying a potential loss of 55% from current levels. This scenario would likely unfold over 6-12 months if the next few quarterly reports show integration struggles or guidance cuts.
